Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibition and lifestyle intervention in prediabetes and early chronic kidney disease
2021-005721-25Phase 4Active
- Sponsor
- University Hospital Tübingen
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in chronic kidney disease (CKD) and prediabetes comparing Dapagliflozin (Forxiga) + lifestyle intervention with Placebo + lifestyle intervention (2 arms). Started Jan 2023; status: active.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)prediabetes
Beyond the preview
Go deeper on 2021-005721-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005721-25.